Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Grace Therapeutics Inc. (ACST:NASDAQ), powered by AI.
Grace Therapeutics Inc. is currently trading at $2.50. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Grace Therapeutics Inc. on Alpha Lenz.
Grace Therapeutics Inc.'s P/E ratio is -1.4.
“Grace Therapeutics Inc. trades at a P/E of -1.4 (undervalued) with modest ROE of -19.8%.”
Ask for details →Grace Therapeutics Inc. is a biopharmaceutical company that specializes in the development of innovative therapies aimed at treating unmet medical needs, particularly in the field of rare and complex diseases. The company's primary focus is on optimizing drug delivery systems to enhance the efficacy and safety of existing therapeutics. Grace Therapeutics Inc. employs advanced technologies to reformulate existing molecules, thereby improving their bioavailability and therapeutic outcomes. Operating within the healthcare and life sciences sectors, Grace Therapeutics plays a transformative role by addressing critical gaps in current treatment options. It touches on various therapeutic areas, potentially offering novel solutions for conditions that have seen limited progress with standard approaches. By leveraging sophisticated drug reformulation techniques, the company seeks to improve patient adherence and outcomes, catering to both domestic and international markets. With a commitment to stringent research and development, Grace Therapeutics contributes significantly to the pharmaceutical industry's efforts to innovate and deliver more personalized and effective treatment solutions. Its strategic initiatives and collaborations position it as an influential player in the advancement of medical therapies, marking its significance in the healthcare market.
“Grace Therapeutics Inc. trades at a P/E of -1.4 (undervalued) with modest ROE of -19.8%.”
Ask for details →Grace Therapeutics Inc. (ticker: ACST) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). Market cap is $19M.
The current price is $2.5 with a P/E ratio of -1.45x and P/B of 0.3x.
ROE is -19.82%.